Inflammation Clinical Trial
— HerbieOfficial title:
Herbal Preparation and Glucose Homeostasis
Rationale: The incidence of obesity and type 2 diabetes (T2D) is increasing rapidly and
accounts for a considerable part of health care costs. Herbal supplements are used in many
cultures for the prevention and treatment of many different conditions. Due to lack of
scientific proof, the application in western cultures are minimal. Animal studies have shown
that many constituents of such herbal supplements may have beneficial effects on several
important parameters known to be affected in T2D. Still, no scientific proof in humans is
available. We therefore aim to investigate the effect of 4-week herbal supplementation on
glucose metabolism, lipid metabolism, vascular function and inflammation in subjects with
increased fasting glucose levels or a decreased glucose tolerance.
Objective: The primary objectives are to investigate if 4-week herbal supplementation in
subjects with increased fasting glucose levels or a decreased glucose tolerance has a
positive effect on blood glucose levels and glucose tolerance. The secondary objectives are
to investigate if 4-week herbal supplementation in subjects with increased fasting glucose
levels or a decreased glucose tolerance has a positive effect on triglycerides (TG), total
cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels,
inflammation, adipose tissue and white blood cell gene-expression and AIX both fasted and
during an OGTT test.
Study design: This study is a randomized, double-blind, placebo controlled cross-over trial
in which two different treatments will be evaluated e.g. an intervention with the herbal
mixture and a placebo. Each person will obtain both treatments in random order for four
weeks with a wash out period of four weeks in-between. Fasting blood samples will be
collected and subjects will receive a OGTT, paralleled by a PWA before and after 4-week
supplementation.
Furthermore, after 4-week supplement intake we will collect a urine sample and collect an
adipose tissue biopsy. The whole trial will last three months.
Study population: 26 overweight males and females 50-75yrs old with an increased fasting
glucose or with an impaired glucose tolerance.
Intervention: Two intervention periods of 4-weeks in which participants will take three
times a day a supplement of 500mg herbal or placebo.
Main study parameters/endpoints: Fasting blood glucose levels, glucose tolerance as
determined by an oral glucose tolerance test (OGTT), AIX, triglycerides (TG), total
cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL) levels, PWA,
adipose tissue an white blood cell gene expression and markers of inflammation .
Nature and extent of the burden and risks associated with participation, benefit and group
relatedness: Subjects that will participate in the study will invest a total of 16.5 hours.
Blood collection by vena punctures/insertion of the venflon and the collection of an adipose
tissue biopsy can occasionally cause a local hematoma or bruise and some participants may
report pain or discomfort. The herbal supplements contain small amounts St. John's wort,
which may affect the function of liver enzymes. We will therefore monitor liver function
parameters during the supplementation period. Furthermore, subjects are excluded if they use
medication known to be affected by St. John's wort. Participant will donate 284ml of blood,
dispersed over 12 weeks.
Status | Completed |
Enrollment | 22 |
Est. completion date | February 2014 |
Est. primary completion date | February 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 50 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Males and postmenopausal females For females: menstrual cycle absent for more than 1 year - age 50-70yrs - BMI >27 kg/m2 - Increased fasting glucose or an impaired glucose tolerance (two-hour glucose levels >7.8 mmol/L on the 75-g oral glucose tolerance test or fasting glucose >6.1mmol/L). Exclusion Criteria: - Systolic blood pressure >160mmHg and diastolic blood pressure> 100mmHg - Tobacco smoker - Received inoculations within 2 months of starting the study or planned during the study - Donated or intend to donate blood from 2 months before the study till months after the study. - Unstable body weight (weight gain or loss >5kg in the past three months) - Diagnosed with any long-term medical condition (e.g., diabetes, haemophilia, CVD, anemia, gastrointestinal disease, renal failure, thyroid disorders, cancer, HIV, hepatitis C) - The use of the following medicine: medicine interfering with St Johns Worth such as, inhibitors of the immune system (ciclosporine, tacrolimus, everolimus, temsirolimus and sirolimus), coumarine type anticoagulant medicine (acenocoumarol and fenprocoumon), anti-epileptica (fenobarbital and fenytoïne), theophylline, atorvastatine, simvastatine, digoxine, kinidine, voriconazol, proton pump inhibitors (omeprazole and esomeprazole) and all anti-depressives ( incl. MAO inhibitors and SSRI's). - Abuse of drugs/alcohol - If the participant don't want to sign the informed consent - If the participant don't want to be informed about unexpected findings during the screening or study - Participation in another biomedical study - Additional exclusion criteria for females: Current use of contraceptives containing hormones Current use of hormone replacement therapy |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
Netherlands | Wageningen university | Wageningen | Gelderland |
Lead Sponsor | Collaborator |
---|---|
Wageningen University |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | change in vascular function | by pulse wave analysis (PWA) | baseline and after 4-week supplementation | No |
Other | change in ALAT/ASAT | baseline and after 4 week supplementation | No | |
Other | Urinary metabolites | after 4 week supplementation | No | |
Other | adipose tissue gene expression | by qpcr | after 4 week supplementation | No |
Other | change in markers of inflammation | by PBMC genexpression and plasma cytokines | baseline and after 4 week of supplementation | No |
Primary | change in glucose tolerance | by oral glucose tolerance test (OGTT) | baseline and after 4-week supplementation | No |
Secondary | change in insulin | baseline and after 4-week supplementation | No | |
Secondary | change in TAG | baseline and after 4 week supplementation | No | |
Secondary | change in HbA1c | glycosylated haemoglobin | baseline and after 4 week supplementation | No |
Secondary | change in FFA | baseline and after 4 week supplementation | No | |
Secondary | change in cholesterol | baseline and after 4 week supplementation | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03995979 -
Inflammation and Protein Restriction
|
N/A | |
Completed |
NCT03255187 -
Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT03577223 -
Egg Effects on the Immunomodulatory Properties of HDL
|
N/A | |
Completed |
NCT04383561 -
Relationship Between LRG and Periodontal Disease
|
N/A | |
Active, not recruiting |
NCT03622632 -
Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
|
||
Completed |
NCT06216015 -
Exercise Training and Kidney Transplantation
|
N/A | |
Completed |
NCT04856748 -
Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
|
||
Completed |
NCT05529693 -
Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population
|
N/A | |
Recruiting |
NCT05670301 -
Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
|
N/A | |
Recruiting |
NCT05415397 -
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
|
Phase 3 | |
Recruiting |
NCT05775731 -
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
|
||
Recruiting |
NCT04543877 -
WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study
|
Early Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Completed |
NCT03429920 -
Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors
|
N/A | |
Completed |
NCT06065241 -
Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals.
|
N/A | |
Completed |
NCT05864352 -
The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
|
||
Completed |
NCT03318731 -
Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males
|
N/A | |
Not yet recruiting |
NCT06134076 -
Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota
|
N/A | |
Not yet recruiting |
NCT06422494 -
The Role of the Adrenergic System in Hypoglycaemia Induced Inflammatory Response in People With Type 1 Diabetes and People Without Type 1 Diabetes-RAID-II
|
N/A |